Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Age
18–71
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of the 12-week treatment period of the predecessor Schering study 97218/300180
Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient
Negative pregnancy test for females
You may not be if
Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study
Clareo Health | Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
